Sava Technologies Raises $19 Million Series A to Advance Next-Gen Wearable Biosensors for Real-Time Health Monitoring
Sava Technologies, the London-based medtech startup that’s re-imagining how we monitor health at the molecular level, has just secured a US$19 million Series A funding round. The new capital will help accelerate its mission to bring next-generation wearable biosensors into real-world use.
Founded in 2019 by bio-engineers Renato Circi and Rafaël Michali (both alumni of Imperial College London), Sava has developed a microsensor platform capable of detecting biomarkers beneath the skin in real time. Their first target is glucose monitoring—a huge market—but their vision extends to multiple molecules and broader preventative health.
Clinical results published by Sava show its device delivered reliable readings for up to 10 days of continuous wear in a patient trial. That’s a milestone in the microsensor world, where most comparable devices struggle to last half that. According to Sava, this performance brings it closer to commercial readiness and heightens interest from regulators and healthcare providers.
The Series A round was led by Balderton Capital and Pentland Ventures, with participation from new investors including Norrsken VC and JamJar Investments. With this round, Sava’s total funding to date rises to around US$32 million.
Sava plans to use the new funds to grow its team, ramp up automated manufacturing of its biosensor modules, and accelerate regulatory approval and commercialisation of its first wearable product. The company aims not just to build a single device, but to expand into what it describes as “real-time, multi-biomarker sensing” for preventative and personalized care. From here, glucose is just the beginning.
The wearable health-tech market is massive. Continuous glucose monitors alone already clock in at more than US$11 billion annually, and Sava sees its technology unlocking access for people who have been previously excluded—thanks to high cost or invasiveness of current solutions. By making it less painful, more affordable and longer-lasting, the company is targeting both patients and broader health-conscious consumers.
What sets Sava apart is its focus on microsensors and multi-analyte capability. Rather than simply tracking one molecule, the platform is designed to scale. The founders have stressed that once glucose monitoring is working, the same architecture can be configured for other biomarkers—opening up future use-cases in wellness, chronic disease management, and even sports. The modular nature of the tech positions Sava for a broader leap beyond the diabetes market.
In the startup funding world, the investor mix signals confidence. Balderton and Pentland are well-known names in European tech funding, and Norrsken’s involvement highlights Sava’s potential impact dimension. JamJar’s participation adds the consumer-tech angle. The fact that global VCs are backing a health-hardware play (not just software) indicates belief in the team, the data, and the market opportunity.
As Sava rolls forward, the next milestones will be crucial: scaling manufacturing, achieving regulatory clearance (medical-device approval worldwide is no small feat), and launching the product into real patient populations. If successful, the company could make wearable biosensing much more accessible—moving healthcare from reactive to proactive, and from episodic check-ups to continuous insight.
For now, Sava Technologies is pointing confidently toward what comes next: a device you wear comfortably that monitors your body’s molecules in real time, IoT-style for health. With new funding in hand and a promising early clinical result, the company is one to watch as the wearable health-tech evolution continues.
